Entry Detail


General Information

Database ID:TRD05504
Confidence:Very High
Contents:>> tsRNA Information
>> tsRNA Association Statistics
>> Disease Information
>> Disease Association Statistics
>> Evidence Support
>> Reference



tsRNA Information

tsRNA Name:tRF-Val-CAC-010
tsRNA Type:N/A
Amino acid and Anticodon:N/A
Sequence:N/A
Related Target:N/A
Predicted Target:N/A
External Links:
MINTbase ID:N/A
tRFdb ID:N/A



tsRNA Association Statistics

Total Associated Disease Number:5
More Information
Network:
(Display the first 15 nodes)



Disease Information

 MeSHDisease Ontology
Disease ID:D000077192DOID:3910
Disease Name:Adenocarcinoma of Lunglung adenocarcinoma
Category:MeSHDisease Ontology
Type:Neoplasmsdisease of cellular proliferation//disease of anatomical entity
Define:A carcinoma originating in the lung and the most common lung cancer type in never-smokers. Malignant cells exhibit distinct features such as glandular epithelial, or tubular morphology. Mutations in KRAS, EGFR, BRAF, and ERBB2 genes are associated with this cancer.A lung non-small cell carcinoma that derives_from epithelial cells of glandular origin.
Alias:Lung Adenocarcinomaadenocarcinoma of lung//bronchogenic lung adenocarcinoma//nonsmall cell adenocarcinoma [EXACT]



Disease Association Statistics

Total Associated tsRNA Number:2
More Information
Network:
(Display the first 15 nodes)



Evidence Support

Strong Evidence:PCR//Western blot//Transfection//Scratch wound healing assay//Cell proliferation assay//Transwell assay//Cell cycle assay//Cell apoptosis assay
Weak Evidence:Sequencing



Reference

[1] PubMed ID:39169309
Disease Name:lung adenocarcinoma
Tissue:Lung
Dysfunction Pattern:Down-Regulation
Validated Method:PCR//Western blot//Transfection//Scratch wound healing assay//Cell proliferation assay//Transwell assay//Cell cycle assay//Cell apoptosis assay//Sequencing
Description:The expression level of tRF-Val-CAC-010 was upregulated in A549 and PC9 LUAD cells
Comparision:Cancer VS Normal
Mechanism:Suppression of tRF-Val-CAC-010 expression resulted in decreased proliferation of A549 and PC9 cells (P < 0.001), reduced invasion and migration of A549 (P < 0.05, P < 0.001) and PC9 cells (P < 0.05, P < 0.01), enhanced apoptosis in both A549 (P < 0.05) and PC9 cells (P < 0.05), and increased G2 phase cell cycle arrest in A549 cells (P < 0.05). In vivo, the tumor formation volume in the tRF-inhibitor group was significantly smaller than that in the model and tRF-NC groups (P < 0.05).